InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
September 03, 2024 07:30 ET
|
InflaRx N.V.
JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced...